Target Binding Site Detail
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T63505 | Target Info | |||
| Target Name | Tyrosine-protein kinase ABL1 (ABL) | ||||
| Synonyms | p150; Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1 | ||||
| Target Type | Successful Target | ||||
| Gene Name | ABL1 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Ligand General Information | Top | ||||
|---|---|---|---|---|---|
| Ligand Name | Myristic acid | Ligand Info | |||
| Canonical SMILES | CCCCCCCCCCCCCC(=O)O | ||||
| InChI | 1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16) | ||||
| InChIKey | TUNFSRHWOTWDNC-UHFFFAOYSA-N | ||||
| PubChem Compound ID | 11005 | ||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| PDB ID: 1OPL Structural basis for the auto-inhibition of c-Abl tyrosine kinase | ||||||
| Method | X-ray diffraction | Resolution | 3.42 Å | Mutation | Yes | [1] |
| PDB Sequence |
DPNLFVALYD
90 FVASGDNTLS100 ITKGEKLRVL110 GYNHNGEWCE120 AQTKNGQGWV130 PSNYITPVNS 140 LEKHSWYHGP150 VSRNAAEYLL160 SSGINGSFLV170 RESESSPGQR180 SISLRYEGRV 190 YHYRINTASD200 GKLYVSSESR210 FNTLAELVHH220 HSTVADGLIT230 TLHYPAPKRN 240 KPTVYGVSPN250 YDKWEMERTD260 ITMKHKLGGG270 QYGEVYEGVW280 KKYSLTVAVK 290 TLKEDTMEVE300 EFLKEAAVMK310 EIKHPNLVQL320 LGVCTREPPF330 YIITEFMTYG 340 NLLDYLRECN350 RQEVNAVVLL360 YMATQISSAM370 EYLEKKNFIH380 RNLAARNCLV 390 GENHLVKVAD400 FGLSRLMTGD410 TYTAHAGAKF420 PIKWTAPESL430 AYNKFSIKSD 440 VWAFGVLLWE450 IATYGMSPYP460 GIDLSQVYEL470 LEKDYRMERP480 EGCPEKVYEL 490 MRACWQWNPS500 DRPSFAEIHQ510 AFETMFQESS520 ISDEVEKELG530 K |
|||||
|
|
||||||
| PDB ID: 2FO0 Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase | ||||||
| Method | X-ray diffraction | Resolution | 2.27 Å | Mutation | Yes | [2] |
| PDB Sequence |
ARWNKENLLA
75 GPSENDPNLF85 VALYDFVASG95 DNTLSITKGE105 KLRVLGYNHN115 GEWCEAQTKN 125 GQGWVPSNYI135 TPVNSLEKHS145 WYHGPVSRNA155 AEYLLSSGIN165 GSFLVRESES 175 SPGQRSISLR185 YEGRVYHYRI195 NTASDGKLYV205 SSESRFNTLA215 ELVHHHSTVA 225 DGLITTLHYP235 APKRNKPTVY245 GVSPNYDKWE255 MERTDITMKH265 KLGGGQYGEV 275 YEGVWKKYSL285 TVAVKTLKED295 TMEVEEFLKE305 AAVMKEIKHP315 NLVQLLGVCT 325 REPPFYIITE335 FMTYGNLLDY345 LRECNRQEVN355 AVVLLYMATQ365 ISSAMEYLEK 375 KNFIHRNLAA385 RNCLVGENHL395 VKVADFGLSR405 LMTGDTYTAH415 AGAKFPIKWT 425 APESLAYNKF435 SIKSDVWAFG445 VLLWEIATYG455 MSPYPGIDLS465 QVYELLEKDY 475 RMERPEGCPE485 KVYELMRACW495 QWNPSDRPSF505 AEIHQAFETM515 FQESSISDEV 525 EKELG
|
|||||
|
|
||||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003 Mar 21;112(6):859-71. | ||||
| REF 2 | Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 2006 Mar 17;21(6):787-98. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.